Size: | Price | Quantity | |
---|---|---|---|
10 mg | $40.00 | ||
50 mg | $140.00 |
Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7
References/Citations:
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Favipiravir (259793-96-9) is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir.1,2,3 It displayed no cytotoxicity in a variety of cells. Favipiravir selectively inhibits viral RNA-dependent RNA polymerase.4 Favipiravir has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses.5 In clinical trials for treatment of SARS-CoV-2.6,7
References/Citations:
1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977
2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235
3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517
4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981
5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446
6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58
7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int. J. Mol. Sci., 21 E2657
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.